Progression-Free Survival in Patients With Cholangiocarcinoma With or Without FGF/FGFR Alterations: A FIGHT-202 Post Hoc Analysis of Prior Systemic Therapy Response

por Bibeau, Kristen, Féliz, Luis, Lihou, Christine F., Ren, Haobo, Abou-Alfa, Ghassan K.
Publicado 2022

FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements

por Bekaii-Saab, Tanios S, Valle, Juan W, Cutsem, Eric Van, Rimassa, Lorenza, Furuse, Junji, Ioka, Tatsuya, Melisi, Davide, Macarulla, Teresa, Bridgewater, John, Wasan, Harpreet, Borad, Mitesh J, Abou-Alfa, Ghassan K, Jiang, Ping, Lihou, Christine F, Zhen, Huiling, Asatiani, Ekaterine, Féliz, Luis, Vogel, Arndt
Publicado 2020